The Moderna cancer vaccine offers hope — now we must speed up personalized therapies

A positive clinical trial of Moderna's personalized mRNA cancer vaccine (mRNA-4157/V940, in combination with pembrolizumab) has demonstrated promising results in treating cancer, reinforcing the therapeutic potential of individualized neoantigen vaccines. Nature's editorial emphasizes that while the trial data are encouraging, significant research and infrastructure challenges remain before personalized cancer vaccines can be widely deployed in clinical practice. The commentary calls for accelerated efforts to streamline neoantigen identification, vaccine manufacturing timelines, and regulatory pathways to bring these therapies to patients faster.